









Markets
/
Stocks
/
nasdaq-celz
/

Creative Medical Technology Holdings Inc

CELZ

1.930USD

+0.150+8.43%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

4.98MMarket Cap

LossP/E TTM



Creative Medical Technology Holdings Inc

1.930

+0.150+8.43%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Creative Medical Technology Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

Creative Medical Technology Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 116 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Creative Medical Technology Holdings Inc's Score

Industry at a Glance

Industry Ranking

116 / 392

Overall Ranking

250 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Creative Medical Technology Holdings Inc Highlights

StrengthsRisks

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

Growing

The company is in a growing phase, with the latest annual income totaling USD 11.00K.

Fairly Valued

The company’s latest PE is -0.66, at a medium 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 25.87K shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

20.000

Target Price

+1023.60%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Creative Medical Technology Holdings Inc is 7.70, ranking 84 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.72

Change

-0.02



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.05

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.85

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.60

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Creative Medical Technology Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Creative Medical Technology Holdings Inc is 7.55, ranking 102 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.66, which is -39.29% below the recent high of -0.40 and -170.46% above the recent low of -1.79.

Score

Industry at a Glance

Previous score

7.55

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 116/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Creative Medical Technology Holdings Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 20.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

20.000

Target Price

+1023.60%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Creative Medical Technology Holdings Inc

CELZ

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Creative Medical Technology Holdings Inc is 6.47, ranking 240 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.35 and the support level at 1.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.18

Change

0.29

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.014

Sell

RSI(14)

44.552

Neutral

STOCH(KDJ)(9,3,3)

23.384

Neutral

ATR(14)

0.160

Low Volatility

CCI(14)

-122.890

Sell

Williams %R

71.154

Sell

TRIX(12,20)

-0.265

Sell

StochRSI(14)

64.792

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.952

Sell

MA10

2.022

Sell

MA20

2.018

Sell

MA50

2.139

Sell

MA100

2.781

Sell

MA200

2.707

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Creative Medical Technology Holdings Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 11.84%, representing a quarter-over-quarter decrease of 0.33%. The largest institutional shareholder is The Vanguard, holding a total of 25.87K shares, representing 0.74% of shares outstanding, with 6.47% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

25.87K

+46.74%

Geode Capital Management, L.L.C.

23.26K

+11.40%

Creative Medical Health, Inc.

22.70K

DRW Securities, LLC

15.10K

Warbington (Timothy)

12.21K

Osaic Holdings, Inc.

1.13K

Edward Jones

1.00K

Finger (Michael H.)

351.00

Fidelity Management & Research Company LLC

200.00

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Creative Medical Technology Holdings Inc is 1.65, ranking 298 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.08. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.